Bioxcel Therapeutics (BTAI)

$1.79

-0.07

(-3.76%)

Market is closed - opens 7 PM, 30 May 2024

Performance

  • $1.78
    $1.87
    $1.79
    downward going graph

    0.56%

    Downside

    Day's Volatility :4.81%

    Upside

    4.28%

    downward going graph
  • $1.78
    $22.06
    $1.79
    downward going graph

    0.56%

    Downside

    52 Weeks Volatility :91.93%

    Upside

    91.89%

    downward going graph

Returns

PeriodBioxcel Therapeutics
3 Months
-43.71%
6 Months
-52.89%
1 Year
-90.55%
3 Years
-94.78%

Highlights

Market Capitalization
69.8M
Book Value
- $2.15
Earnings Per Share (EPS)
-5.21
Wall Street Target Price
8.25
Profit Margin
0.0%
Operating Margin TTM
-4151.72%
Return On Assets TTM
-66.96%
Return On Equity TTM
-1766.94%
Revenue TTM
1.8M
Revenue Per Share TTM
0.06
Quarterly Revenue Growth YOY
182.5%
Gross Profit TTM
355.0K
EBITDA
-140.3M
Diluted Eps TTM
-5.21
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.54
EPS Estimate Next Year
-1.68
EPS Estimate Current Quarter
-0.7
EPS Estimate Next Quarter
-0.71

Analyst Recommendation

Buy
    69%Buy
    30%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Bioxcel Therapeutics(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
10
Hold
4
5
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 360.89%

Current $1.79
Target $8.25

Technicals Summary

Sell

Neutral

Buy

Bioxcel Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin

Institutional Holdings

  • FMR Inc

    6.80%
  • BlackRock Inc

    3.71%
  • Vanguard Group Inc

    2.97%
  • Ameriprise Financial Inc

    1.46%
  • Geode Capital Management, LLC

    1.22%
  • State Street Corporation

    1.19%

Company Information

bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

Organization
Bioxcel Therapeutics
Employees
74
CEO
Dr. Vimal D. Mehta Ph.D.
Industry
Health Technology

FAQs